Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
gptkb:nilotinib
|
| gptkbp:approvedBy |
gptkb:FDA
2007 |
| gptkbp:ATCCode |
gptkb:L01XE08
|
| gptkbp:brand |
gptkb:Tasigna
|
| gptkbp:CASNumber |
gptkb:641571-10-0
|
| gptkbp:contraindication |
CYP3A4 inhibitors
QT-prolonging drugs |
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:discoveredIn |
2002
|
| gptkbp:hasMolecularFormula |
gptkb:C28H22F3N7O
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMN107
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:sideEffect |
nausea
headache rash QT prolongation myelosuppression |
| gptkbp:target |
gptkb:BCR-ABL
gptkb:PDGFR gptkb:c-Kit |
| gptkbp:usedFor |
gptkb:chronic_myeloid_leukemia
gptkb:Philadelphia_chromosome-positive_acute_lymphoblastic_leukemia |
| gptkbp:bfsParent |
gptkb:nilotinib
|
| gptkbp:bfsLayer |
6
|